JP2019523260A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019523260A5 JP2019523260A5 JP2019503646A JP2019503646A JP2019523260A5 JP 2019523260 A5 JP2019523260 A5 JP 2019523260A5 JP 2019503646 A JP2019503646 A JP 2019503646A JP 2019503646 A JP2019503646 A JP 2019503646A JP 2019523260 A5 JP2019523260 A5 JP 2019523260A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- item
- amino acids
- peptide agent
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 83
- 239000003795 chemical substances by application Substances 0.000 claims description 79
- 150000001413 amino acids Chemical class 0.000 claims description 77
- -1 cationic amino acids Chemical class 0.000 claims description 18
- 230000002209 hydrophobic effect Effects 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 150000008574 D-amino acids Chemical class 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 claims description 7
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical group 0.000 claims description 6
- 210000004899 c-terminal region Anatomy 0.000 claims description 5
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 230000006540 mitochondrial respiration Effects 0.000 claims description 4
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000004065 mitochondrial dysfunction Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 150000008575 L-amino acids Chemical class 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 description 74
- 238000000034 method Methods 0.000 description 9
- 125000002091 cationic group Chemical group 0.000 description 8
- 238000009472 formulation Methods 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- 230000002438 mitochondrial effect Effects 0.000 description 4
- SFVLTCAESLKEHH-WKAQUBQDSA-N (2s)-6-amino-2-[[(2s)-2-[[(2r)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-n-[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]hexanamide Chemical compound CC1=CC(O)=CC(C)=C1C[C@H](NC(=O)[C@H](N)CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N)=O)CC1=CC=CC=C1 SFVLTCAESLKEHH-WKAQUBQDSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 108010033284 arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide Proteins 0.000 description 3
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 3
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 2
- 241001559542 Hippocampus hippocampus Species 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010053961 Mitochondrial toxicity Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 229940124280 l-arginine Drugs 0.000 description 2
- 231100000296 mitochondrial toxicity Toxicity 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000037050 permeability transition Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 229910052717 sulfur Chemical group 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662321168P | 2016-04-11 | 2016-04-11 | |
| US62/321,168 | 2016-04-11 | ||
| PCT/US2017/026869 WO2017180535A1 (en) | 2016-04-11 | 2017-04-10 | Chiral peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019523260A JP2019523260A (ja) | 2019-08-22 |
| JP2019523260A5 true JP2019523260A5 (https=) | 2020-03-12 |
Family
ID=60042852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503646A Ceased JP2019523260A (ja) | 2016-04-11 | 2017-04-10 | キラルペプチド |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10870678B2 (https=) |
| EP (1) | EP3442990A4 (https=) |
| JP (1) | JP2019523260A (https=) |
| CN (1) | CN109563131A (https=) |
| AU (2) | AU2017249218B2 (https=) |
| CA (1) | CA3020393A1 (https=) |
| WO (1) | WO2017180535A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3898653A4 (en) | 2018-12-18 | 2022-08-24 | Stealth BioTherapeutics Inc. | ANALOGS TARGETING MITOCHONDRIAL DISEASES |
| US12404300B2 (en) | 2018-12-18 | 2025-09-02 | Stealth Biotherapeutics Inc. | Mitochondria-targeting peptides |
| US12215173B2 (en) | 2019-08-07 | 2025-02-04 | HUMANWELL PHARMACEUTICAL US, Inc. | Kappa opioid receptor peptide amide ligands |
| US20210255196A1 (en) * | 2020-01-17 | 2021-08-19 | Waters Technologies Corporation | Low binding surfaces for peptide mapping |
| EP4114429A2 (en) * | 2020-03-06 | 2023-01-11 | Allegro Pharmaceuticals, LLC | Treatments for improving or lessening impairment of mitochondrial function |
| KR20230024419A (ko) | 2020-06-25 | 2023-02-20 | 휴먼웰 파마슈티컬 유에스 | 의학적 장애 치료용 펩티드 |
| CN117881411A (zh) | 2021-06-01 | 2024-04-12 | 艾迪雅生物有限责任公司 | 用于眼部药物的延长释放药物递送系统和使用方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2656854T1 (sl) | 2003-02-04 | 2015-09-30 | Cornell Research Foundation, Inc. | Uporabe aromatsko-kationskega peptida |
| WO2008154373A1 (en) | 2007-06-07 | 2008-12-18 | Institute For Hepatitis And Virus Research | 2-amino-2,7-dideoxy-alpha-d-glycero-d-gluco-heptopyranosyl inhibitors of positive sense single-stranded rna envelope viruses |
| CA2701274A1 (en) * | 2007-10-02 | 2009-04-09 | Mdrna, Inc. | Lipopeptides for delivery of nucleic acids |
| DK2262520T3 (en) | 2008-02-26 | 2017-08-07 | Univ Cornell | COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury |
| JP5238297B2 (ja) | 2008-03-04 | 2013-07-17 | シャープ株式会社 | 認証方法および入力装置 |
| EP3563862B1 (en) * | 2009-03-20 | 2021-05-05 | The General Hospital Corporation d/b/a Massachusetts General Hospital | D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries |
| CN105031605A (zh) * | 2009-08-12 | 2015-11-11 | 康奈尔大学 | 预防或治疗代谢综合症的方法 |
| PL2470191T3 (pl) | 2009-08-24 | 2014-09-30 | Stealth Peptides Int Inc | Sposoby i kompozycje do profilaktyki lub leczenia stanów okulistycznych |
| EP2485749A4 (en) | 2009-10-05 | 2013-07-24 | Univ Cornell | METHOD FOR THE PREVENTION AND TREATMENT OF HEART FAILURE |
| EP3266462A1 (en) | 2009-12-31 | 2018-01-10 | Stealth Peptides International, Inc. | Methods for performing a coronary artery bypass graft procedure |
| AU2011207432A1 (en) | 2010-01-25 | 2012-08-02 | Cornell University | Aromatic-cationic peptides and uses of same |
| EP3332795A1 (en) | 2010-02-26 | 2018-06-13 | Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") | Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy |
| JP2013532124A (ja) | 2010-05-03 | 2013-08-15 | ステルス ペプチドズ インターナショナル インコーポレイテッド | 芳香族系陽イオンペプチド及びその使用 |
| JP6319738B2 (ja) | 2010-07-09 | 2018-05-09 | ステルス ペプチドズ インターナショナル インコーポレイテッド | 虚血／再灌流障害に続くノーリフローの予防又は処置方法 |
| CA2831151A1 (en) | 2011-03-24 | 2012-09-27 | Cornell University | Aromatic-cationic peptides and uses of same |
| AU2012271691A1 (en) | 2011-06-14 | 2014-01-16 | Stealth Peptides International, Inc. | Aromatic-cationic peptides and uses of same |
| AU2012315586B2 (en) | 2011-09-29 | 2017-07-20 | Mayo Foundation For Medical Education And Research | Aromatic-cationic peptides and methods for using same |
| WO2013059071A1 (en) | 2011-10-17 | 2013-04-25 | Cornell University | Aromatic-cationic peptides and uses of same |
| EP3009141A1 (en) * | 2011-12-09 | 2016-04-20 | Stealth Peptides International, Inc. | Aromatic-cationic peptides and uses of same |
| HK1204988A1 (en) | 2012-02-22 | 2015-12-11 | Stealth Peptides International, Inc. | Methods and compositions for preventing or treating ophthalmic conditions |
| CA2865409C (en) | 2012-02-23 | 2020-07-21 | Cornell University | Aromatic-cationic peptides and uses of same |
| JP6317324B2 (ja) | 2012-03-30 | 2018-04-25 | ステルス ペプチドズ インターナショナル インコーポレイテッド | 神経障害を予防および処置するための方法および組成物 |
| CA2870200A1 (en) | 2012-04-12 | 2013-10-17 | Stealth Peptides International, Inc. | Aromatic-cationic peptides and uses of same |
| ES2981865T3 (es) * | 2012-07-11 | 2024-10-10 | Gemvax & Kael Co Ltd | Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo |
| US20140034183A1 (en) | 2012-07-31 | 2014-02-06 | Viz Enterprises, Llc | Cap assembly for dispensing a dispensable component and method of making and using the same |
| AU2013334788A1 (en) | 2012-10-22 | 2015-06-04 | Henry Ford Health Systems | Methods for reducing risks associated with heart failure and factors associated therewith |
| EP2928562A4 (en) | 2012-12-06 | 2016-06-22 | Stealth Peptides Int Inc | PEPTIDE THERAPEUTIC PRODUCTS AND METHODS OF USE |
| CN110339339A (zh) | 2013-03-01 | 2019-10-18 | 康德生物医疗技术公司 | 治疗线粒体疾病的方法 |
| WO2014165607A2 (en) | 2013-04-02 | 2014-10-09 | Stealth Peptides International, Inc. | Aromatic-cationic peptide formulations, compositions and methods of use |
| CA2919992C (en) | 2013-08-01 | 2022-08-09 | Stealth Biotherapeutics Corp | Methods and compositions for preventing or treating leber's hereditary optic neuropathy |
| WO2015023680A1 (en) | 2013-08-12 | 2015-02-19 | Stealth Peptides International, Inc. | Combination therapy for the treatment of ischemia-reperfusion injury |
| JP6480921B2 (ja) | 2013-09-27 | 2019-03-13 | コーネル ユニヴァーシティー | コレステロール誘発性ミトコンドリア機能不全を治療するための芳香族カチオン性ペプチドの使用 |
| EP3052115A4 (en) * | 2013-09-30 | 2017-09-27 | Cornell University | Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity |
| EP3060573B1 (en) | 2013-10-23 | 2019-07-17 | Kaneka Corporation | Tetrapeptide compound and method for producing same |
| CA2932408A1 (en) | 2013-12-02 | 2015-06-11 | Stealth Biotherapeutics Corp | Compositions and methods for treating vitiligo |
| JP6626446B2 (ja) | 2013-12-27 | 2019-12-25 | ステルス バイオセラピューティックス コープ | 薬学的に適切な芳香族カチオン性ペプチド |
| EP2913287B1 (en) | 2014-02-26 | 2018-01-03 | Otis Elevator Company | Governor for controlling the speed of a hoisted object relative to a guide member |
| HK1231493A1 (zh) | 2014-03-03 | 2017-12-22 | Stealth Biotherapeutics Corp | 药学上相关的芳香族阳离子肽 |
| WO2016004441A1 (en) | 2014-07-03 | 2016-01-07 | Stealth Peptides International, Inc. | Methods for the prevention or treatment of acute myocardial infarction injury |
-
2017
- 2017-04-10 CA CA3020393A patent/CA3020393A1/en not_active Abandoned
- 2017-04-10 AU AU2017249218A patent/AU2017249218B2/en not_active Ceased
- 2017-04-10 WO PCT/US2017/026869 patent/WO2017180535A1/en not_active Ceased
- 2017-04-10 CN CN201780031671.6A patent/CN109563131A/zh active Pending
- 2017-04-10 US US16/092,093 patent/US10870678B2/en not_active Expired - Fee Related
- 2017-04-10 JP JP2019503646A patent/JP2019523260A/ja not_active Ceased
- 2017-04-10 EP EP17782934.8A patent/EP3442990A4/en not_active Withdrawn
-
2020
- 2020-09-03 US US17/011,264 patent/US20200407395A1/en not_active Abandoned
- 2020-10-29 AU AU2020260489A patent/AU2020260489A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019523260A5 (https=) | ||
| KR100352541B1 (ko) | 노나-및데카펩타이드와,이를포함하는후천성면역결핍증치료용약제학적조성물 | |
| CA2272990C (en) | Heptapeptide oxytocin analogues | |
| US9938320B2 (en) | Peptides for promoting angiogenesis and use thereof | |
| CA2097192C (en) | Bombesin antagonists | |
| CA2688161A1 (en) | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | |
| CN115957296A (zh) | 药物组合物 | |
| EP2841084B1 (en) | Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer | |
| US20080305989A1 (en) | Transdermal delivery peptides and method of use thereof | |
| AU2023285759B2 (en) | DPEP-1 binding compositions and methods of use | |
| JPS61293997A (ja) | 生活性リジン含有オクタペプチド及びその調整方法 | |
| CN108472329B (zh) | 多肽刺激免疫系统的用途 | |
| KR20110112303A (ko) | 항종양 활성을 가지는 노나펩티드 | |
| US20250333443A1 (en) | Dpep-1 binding agents and methods of use | |
| US20250002854A1 (en) | Methods of generating populations of tumour-infiltrating t cells | |
| KR20210093958A (ko) | 미토콘드리아 질환을 표적으로 하는 유사체 | |
| US9249185B2 (en) | Peptides for promoting angiogenesis and an use thereof | |
| CA3193223A1 (en) | Radiolabeled ligands for targeted pet/spect imaging and methods of their use | |
| EP1827476B1 (en) | Use of bombesin/gastrin-releasing peptide antagonist for the treatment of sepsis, septic shock, acute lung injury or rheumatoid arthritis | |
| CN110139659B (zh) | 用于治疗干燥综合征的肽 | |
| US12194034B2 (en) | Neutrophil exocytosis inhibitors | |
| US5593965A (en) | Anti-tumor effects of GnRH-III | |
| JPH10130163A (ja) | アルツハイマー病の治療および予防用医薬の製造のためのブラジキニン拮抗薬の使用 | |
| WO2016004441A1 (en) | Methods for the prevention or treatment of acute myocardial infarction injury | |
| HK40012327A (en) | Peptides for treating sjogren's syndrome |